Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?

• Published in: BioMed research international Vol. 2015; no. 2015; pp. 1 - 10
• Main Authors: Silva Junior, Wellington Santana da, Godoy-Matos, Amelio Fernando de, Kraemer-Aguiar, Luiz Guilherme
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2015; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Atherosclerosis; Atherosclerosis - complications; Atherosclerosis - drug therapy; Atherosclerosis - metabolism; Bioavailability; Cell adhesion & migration; Clinical trials; Confidence intervals; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Dipeptidyl Peptidase 4 - genetics; Dipeptidyl Peptidase 4 - metabolism; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Endocrinology; Enzymes; Gangrene; Glucose; Health aspects; Humans; Incretins - metabolism; Inflammation - drug therapy; Inflammation - metabolism; Inflammation - pathology; Insulin; Insulin resistance; Physiological aspects; Polypeptides; Proteases; Proteins; Review; Studies
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2015/816164

Type 2 diabetes mellitus (T2DM) has become one of the most prevalent noncommunicable diseases in the past years. It is undoubtedly associated with atherosclerosis and increased risk for cardiovascular diseases. Incretins, which are intestinal peptides secreted during digestion, are able to increase insulin secretion and its impaired function and/or secretion is involved in the pathophysiology of T2DM. Dipeptidyl peptidase 4 (DPP4) is an ubiquitous enzyme that regulates incretins and consequently is related to the pathophysiology of T2DM. DPP4 is mainly secreted by endothelial cells and acts as a regulatory protease for cytokines, chemokines, and neuropeptides involved in inflammation, immunity, and vascular function. In T2DM, the activity of DPP4 seems to be increased and there are a growing number of in vitro and in vivo studies suggesting that this enzyme could be a new link between T2DM and atherosclerosis. Gliptins are a new class of pharmaceutical agents that acts by inhibiting DPP4. Thus, it is expected that gliptin represents a new pharmacological approach not only for reducing glycemic levels in T2DM, but also for the prevention and treatment of atherosclerotic cardiovascular disease in diabetic subjects. We aimed to review the evidences that reinforce the associations between DPP4, atherosclerosis, and T2DM.